| Literature DB >> 34083347 |
Toby O Smith1,2, Pippa Belderson2, Jack R Dainty2, Linda Birt2, Karen Durrant2, Jacqueline R Chipping2, Jordan Tsigarides2,3, Max Yates2,3, Felix Naughton2, Sarah Werry2, Caitlin Notley2, Lee Shepstone2, Alex J MacGregor4,3.
Abstract
OBJECTIVES: To determine the impact of COVID-19 pandemic social restriction measures on people with rheumatic and musculoskeletal diseases (RMDs) and to explore how people adapted to these measures over time.Entities:
Keywords: COVID-19; musculoskeletal disorders; pain management; rheumatology
Year: 2021 PMID: 34083347 PMCID: PMC8182755 DOI: 10.1136/bmjopen-2021-048772
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Respondent characteristics and responses to health provision access from online survey at baseline
| Characteristics | Frequency (%) | |
| N | 703 | |
| Gender | Female | 574 (82.0) |
| Male | 126 (18.0) | |
| Non-binary | 1 (0.1) | |
| Prefer to self-describe | 1 (0.1) | |
| Prefer not to say | 1 (0.1) | |
| Age (years) | 18–30 | 21 (3.0) |
| 31–40 | 44 (6.3) | |
| 41–50 | 113 (16.1) | |
| 51–60 | 173 (24.6) | |
| 61–70 | 203 (28.9) | |
| 71–80 | 132 (18.8) | |
| 80+ | 16 (2.3) | |
| Region of respondent | England | 660 (93.9) |
| Scotland | 21 (3.0) | |
| Wales | 19 (2.7) | |
| Northern Ireland | 2 (0.3) | |
| Ethnic group | White | 682 (97.8) |
| Mixed/multiple ethnic group | 4 (0.6) | |
| Asian | 7 (1.0) | |
| Black, African and Caribbean | 3 (0.4) | |
| Arab | 1 (0.1) | |
| RMD diagnosis | Rheumatoid arthritis | 311 (44.2) |
| Osteoarthritis | 152 (21.6) | |
| Mechanical low back pain | 70 (9.9) | |
| Fibromyalgia | 68 (9.6) | |
| Psoriatic arthritis | 64 (9.1) | |
| Inflammatory polyarthritis | 63 (8.9) | |
| Hypermobility | 40 (5.6) | |
| Specific RMD diagnosis not reported | 33 (4.7) | |
| Connective tissue disease (eg, lupus, scleroderma and myositis) | 25 (3.5) | |
| Ankylosing spondylitis | 22 (3.1) | |
| Osteoporosis | 18 (2.5) | |
| Polymyalgia rheumatica | 10 (1.4) | |
| Ligament/tendon injury/bursitis | 9 (1.3) | |
| Neck pain | 6 (0.8) | |
| Gout | 5 (0.7) | |
| Other | 63 (8.9) | |
| How have your RMD symptoms been since the COVID-19 measures started? | Decreased | 45 (6.5) |
| Stayed the same | 287 (41.1) | |
| Increased | 365 (52.4) | |
| Pain (scale: 0–10) | Mean (SD) | 4.8 (2.6) |
| General health (scale: 0–10) | Mean (SD) | 4.1 (2.4) |
| Total Lubben Social Network Score (scale: 0–30) | Mean (SD) | 14.8 (5.5) |
| Total UCLA Loneliness (scale: 3–9) | Mean (SD) | 5.1 (2.0) |
| Difficulty accessing medication | Yes | 82 (11.7) |
| No | 616 (88.3) | |
| Required someone to help access medications | Yes | 309 (44.3) |
| No | 389 (55.7) | |
| Changed medications since COVID-19 outbreak | Yes | 103 (14.8) |
| No | 595 (85.2) | |
| Required to seek advice from a health professional on condition | Yes | 252 (36.1) |
| No | 446 (63.9) | |
| Who did you contact | General practitioner | 158 (22.3) |
| Practice nurse/GP nurse practitioner | 23 (3.2) | |
| Rheumatology department | 97 (13.7) | |
| Physiotherapy or occupational therapist | 16 (2.3) | |
| Pharmacist | 16 (2.3) | |
| Hospital department (non-RMD) | 10 (1.4) | |
| A&E | 3 (0.4) | |
| Private chiropractor, osteopath or massage therapist | 1 (0.1) | |
| Royal Osteoporosis Society | 1 (0.1) | |
| Endocrinology department | 7 (1.0) | |
| Pain clinic | 2 (0.3) | |
| Counsellor or health psychologist | 2 (0.3) | |
| Massage therapist | 1 (0.1) | |
| Podiatrist | 1 (0.1) | |
| Nutritionist | 1 (0.1) | |
| NHS 111 | 2 (0.3) | |
| How easy has it been to get advice? (scale: 0–10) | (Mean (SD) value (scale 0–10) | 4.8 (3.3) |
A&E, accident and emergency; JIA, juvenile inflammatory arthritis; NHS, National Health Service; RMD, rheumatic and musculoskeletal diseases; UCLA, University of California Los Angeles Loneliness Score.
Association at baseline between rheumatic and musculoskeletal disease (RMD) symptoms and selected participant characteristics and questionnaire responses
| χ2 test of association with outcome (symptoms) | ||||
| Decreased | Stable | Increased | P value | |
| n (%) | 45 (6) | 287 (41) | 365 (52) | |
| Age group (years) | 0.017 | |||
| 18–60 | 22 (6) | 125 (36) | 200 (58) | |
| 60 plus | 33 (7) | 162 (46) | 165 (47) | |
| Gender | 0.110 | |||
| Male | 8 (7) | 60 (49) | 54 (44) | |
| Female | 37 (6) | 224 (39) | 311 (54) | |
| RMD diagnosis* | <0.001 | |||
| RA | 17 (5) | 155 (48) | 149 (46) | |
| IA | 4 (10) | 24 (60) | 12 (30) | |
| PsA | 4 (6) | 22 (34) | 38 (59) | |
| Other | 19 (7) | 83 (31) | 166 (62) | |
| Situation | 0.880 | |||
| At home | 24 (7) | 141 (40) | 191 (54) | |
| Self-isolating | 8 (7) | 49 (40) | 64 (53) | |
| Shielding | 13 (6) | 97 (44) | 110 (50) | |
| Difficulty accessing medication? | 0.103 | |||
| Yes | 4 (5) | 26 (32) | 52 (63) | |
| No | 41 (7) | 261 (42) | 313 (51) | |
| Change medication? | <0.001 | |||
| Yes | 9 (9) | 21 (20) | 73 (71) | |
| No | 36 (6) | 266 (45) | 292 (49) | |
| Consult health professional? | <0.001 | |||
| Yes | 15 (6) | 64 (25) | 172 (69) | |
| No | 30 (7) | 223 (50) | 193 (43) | |
| Physical activity | <0.001 | |||
| Decreased | 31 (7) | 141 (30) | 302 (64) | |
| Same | 3 (3) | 89 (75) | 26 (22) | |
| Increased | 11 (10) | 57 (54) | 37 (35) | |
Data are frequency (%) unless stated otherwise.
*Other=mainly osteoarthritis (55%) but also including any diagnosis that was not RA, IA or PsA (see table 1).
IA, inflammatory arthritis; PsA, psoriatic arthritis; RA, Rheumatoid arthritis; RMD, rheumatic and musculoskeletal diseases.
Figure 1Change in symptoms from baseline over the 10-week follow-up interval. Green points/lines indicate 18–60 age group; Blue points/lines indicate 60+ age group; bar widths represent one standared error of the mean. VAS, visual analogue scale.
Figure 2Change in behaviour outcomes from baseline over the 10-week follow-up interval. Green points/lines indicate 18–60 age group; Blue points/lines indicate 60+ age group; bar widths represent one standared error of the mean.
Interview subsample characteristics (n=26)
| Characteristics | Frequency | |
| Gender | Female | 17 |
| Male | 9 | |
| Age (years) | 18–30 | 1 |
| 31–40 | 4 | |
| 41–50 | 5 | |
| 51–60 | 4 | |
| 61–70 | 3 | |
| 71–80 | 8 | |
| 80+ | 1 | |
| Ethnic group | White | 26 |
| RMD diagnosis | Rheumatoid arthritis | 18 |
| Psoriatic arthritis | 5 | |
| Inflammatory polyarthritis | 1 | |
| Polymyalgia rheumatica | 2 | |
| How have your RMD symptoms been since the COVID-19 measures started? | Decreased | 3 |
| Stayed the same | 9 | |
| Increased | 14 | |
RMD, rheumatic and musculoskeletal diseases.
Key themes generated from the qualitative study – perceived underlying attributions for symptom change
| Experience of symptoms | Attributions from interview data | Representative quote |
| Postponement or cancellation of appointments, treatments and investigations | ||
| Telephone appointments | ||
| Reduced routine activity | ||
| Struggling with household tasks | ||
| Anxiety or low mood associated with the pandemic and being in a clinically vulnerable group. | ||
| Maintaining exercise | ||
| Pre-existing stable or well-controlled condition | ||
| An opportunity for respite, improved well-being | ||
| More opportunity for exercise |